title: L-asparaginase induced hyperlipidaemia in acute lymphoblastic leukaemia.
abstract: OBJECTIVE
  To evaluate hyperlipidaemia in patients with acute lymphoblastic leukaemia (ALL) receiving L-asparaginase.
  
  
  METHODS
  A case-control study carried out between October 2007 and October 2010 with 77 patients undergoing chemotherapy at a teaching children's hospital in Babol, Iran. Patients were treated with anti-leukaemic agents according to the protocols for standard-risk and high-risk ALL. Those patients who received asparaginase represented the cases and those who did not receive it were the controls. Biochemical markers were checked during the induction phase chemotherapy. Lipid profile of patients was recorded. Data was analysed using SPSS 16.
  
  
  RESULTS
  Of the 77 patients, 37 (48.05%) received asparaginase therapy and 40 (51.94%) patients did not.The mean peak triglyceride and cholesterol levels during asparaginase therapy in the first group were significantly higher than the levels in the second group.
  
  
  CONCLUSIONS
  Severe hyperlipidaemia may be the cause of some morbidity in children receiving asparaginase. Asparaginase-induced hyperlipidaemia should be monitored in ALL patients during the induction phase of treatment.
authors.affiliation: Department of Pediatric Haematology, Oncology, Babol University of Medical Sciences, Babol, Iran.
authors.forename: Hassan Mahmoodi
authors.initials: HM
authors.lastname: Nesheli
authors.forename: Ahmad
authors.initials: A
authors.lastname: Tamaddoni
authors.forename: Mohsen Mahmoodi
authors.initials: MM
authors.lastname: Nesheli
authors.forename: Alireza
authors.initials: A
authors.lastname: Yahyai
authors.forename: Fariba
authors.initials: F
authors.lastname: Khabiri
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Hosseinzadeh
authors.forename: Tahereh Galini
authors.initials: TG
authors.lastname: Moghaddam
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects*; D015415:Biomarkers / Q000032:analysis; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D007223:Infant; D007492:Iran; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D001215:Asparaginase